Literature DB >> 31370988

Court personnel attitudes towards medication-assisted treatment: A state-wide survey.

Barbara Andraka-Christou1, Meghan Gabriel2, Jody Madeira3, Ross D Silverman4.   

Abstract

BACKGROUND: Despite its efficacy, medication-assisted treatment (MAT) is rarely available in the criminal justice system in the United States, including in problem-solving courts or diversionary settings. Previous studies have demonstrated criminal justice administrators' hostility towards MAT, especially in prisons and jails. Yet, few studies have examined attitudes among court personnel or compared beliefs among different types of personnel. Also, few studies have explored the relationship between MAT education/training and attitudes. Finally, few studies have directly compared attitudes towards methadone, oral buprenorphine, and extended-release naltrexone in the criminal justice system.
METHODS: We modified a survey by Matusow et al. (2013) to explore justice professionals' MAT attitudes, including associations with demographic variables, court role, and previous MAT education/training. After piloting the survey, we distributed it to a convenience sample of justice professionals registered for an educational summit held in Indiana in 2018. Data was analyzed using descriptive and inferential statistical methods.
RESULTS: 231 Indiana court employees who had registered for a state MAT educational summit completed the survey prior to the summit, including judges, probation officers, law enforcement personnel, attorneys, probation officers, program directors, counselors, and case managers. Overall, participants had significantly more positive attitudes towards extended-release naltrexone than towards other medications (p value <0.01). Court employee average attitudes towards methadone were significantly more negative than average attitudes towards oral buprenorphine; and average attitudes towards oral buprenorphine were significantly more negative than average attitudes towards extended-release naltrexone (p value <0.01). Employment as a prosecutor or law enforcement officer was associated with more negative attitudes towards oral buprenorphine and methadone (p value <0.05). Exposure to previous MAT training was associated with more positive attitudes for all medications (p value <0.05). Compared to participants with graduate degrees, participants with less education had significantly more negative attitudes towards extended-release naltrexone (p < 0.05). Gender, age, rurality, and personal/family recovery history were not associated with differences in attitudes.
CONCLUSION: As expected, court employees' attitudes significantly differ by medication, with average attitudes towards agonist medications being more negative than attitudes towards extended-release naltrexone. Despite a larger evidence base for the efficacy of methadone and oral buprenorphine, justice personnel may have more positive attitudes towards extended-release naltrexone due to targeted marketing by the pharmaceutical manufacturer, fears about diversion or misuse of agonist medications, and historic criminal justice hostility towards agonist medications. Importantly, previous education/training regarding MAT is associated with more positive attitudes, suggesting that more awareness-raising or capacity building educational interventions are needed, especially for prosecutors and law enforcement personnel. Published by Elsevier Inc.

Entities:  

Keywords:  Attitudes; Beliefs; Buprenorphine; Courts; Criminal justice; Education; Medication-assisted treatment; Medications for opioid use disorder; Methadone; Naltrexone; Opioid use disorder; Survey; Training

Year:  2019        PMID: 31370988     DOI: 10.1016/j.jsat.2019.06.011

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  7 in total

1.  Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis.

Authors:  Hefei Wen; Benjamin G Druss; Brendan Saloner
Journal:  Health Aff (Millwood)       Date:  2020-05       Impact factor: 6.301

Review 2.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

3.  Prevalence and risk factors for opioid related mortality among probation clients in an American city.

Authors:  Jordan K Boulger; Keiki Hinami; Thomas Lyons; Juleigh Nowinski Konchak
Journal:  J Subst Abuse Treat       Date:  2021-12-24

4.  A national survey of state laws regarding medications for opioid use disorder in problem-solving courts.

Authors:  Barbara Andraka-Christou; Olivia Randall-Kosich; Matthew Golan; Rachel Totaram; Brendan Saloner; Adam J Gordon; Bradley D Stein
Journal:  Health Justice       Date:  2022-03-31

5.  Barriers to medications for opioid use disorder in the court system: provider availability, provider "trustworthiness," and cost.

Authors:  Fatema Z Ahmed; Barbara Andraka-Christou; M H Clark; Rachel Totaram; Danielle N Atkins; Brandon Del Pozo
Journal:  Health Justice       Date:  2022-07-27

6.  Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine.

Authors:  Gabriel G Edwards; Ayako Miyashita-Ochoa; Enrico G Castillo; David Goodman-Meza; Ippolytos Kalofonos; Raphael J Landovitz; Arleen A Leibowitz; Craig Pulsipher; Ed El Sayed; Steven Shoptaw; Chelsea L Shover; Michelle Tabajonda; Yvonne S Yang; Nina T Harawa
Journal:  AIDS Behav       Date:  2022-09-05

7.  Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.

Authors:  Barbara Andraka-Christou; M H Clark; Danielle N Atkins; Brandon Del Pozo
Journal:  Subst Abus       Date:  2021-07-08       Impact factor: 3.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.